Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03210740 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis
A Phase 2 study, sponsored by AmDerma.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03210740: Completed Phase 2 study, sponsored by AmDerma.
NCT03210740 is a Phase 2 study that has completed, run by AmDerma. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03210740, a Phase 2 study, has completed, sponsored by AmDerma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of Actinic Keratosis (AK) Lesions
Primary Outcome
(100 % of all AK lesions cleared) 8 weeks post treatment
Interventions
- DRUG Vehicle Cream
- DRUG AM001 Cream, 7.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2018-04-24 |
| Phase | Phase 2 |
What the finished NCT03210740 record still lists
NCT03210740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle Cream is the first listed.
NCT03210740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03210740 about?
NCT03210740 is a clinical study titled "Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis". To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of Actinic Keratosis (AK) Lesions
What is the current status of trial NCT03210740?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-06-06. Estimated completion is 2018-04-24.
What interventions are being tested in trial NCT03210740?
The interventions under investigation include: Vehicle Cream (DRUG), AM001 Cream, 7.5% (DRUG).
Who is sponsoring clinical trial NCT03210740?
This trial is sponsored by AmDerma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03210740's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI